Tolerion

Tolerion has developed a novel antigen-specific immune tolerance induction platform to address the root causes of autoimmune diseases. Its lead candidate, TOL‑3021—a tolerizing biologic for type 1 diabetes—has completed a Phase 2 study showing significant improvement in C-peptide levels versus placebo. This biomarker indicates improved pancreatic insulin production and beta cell mass. No disease-modifying drugs currently exist for type 1 diabetes, making this a potentially first-in-class therapy with large market potential. Other pipeline assets target multiple sclerosis and myasthenia gravis; the MS program was discontinued while myasthenia gravis remains pending.[5][2][4]